{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:54:57Z","timestamp":1789732497293,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ejps.2017.05.041","type":"journal-article","created":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T14:15:58Z","timestamp":1495203358000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects"],"prefix":"10.1016","volume":"106","author":[{"given":"Sangeetha","family":"Mathavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momir","family":"Mikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Golocorbin-Kon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0049-6969","authenticated-orcid":false,"given":"Hani","family":"Al-Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejps.2017.05.041_bb0005","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/clinchem\/17.9.915","article-title":"Changes in the saccharoid fraction in rats with alloxan-induced diabetes or injected with epinephrine","volume":"17","author":"Alam","year":"1971","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.ejps.2017.05.041_bb0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1753-5174.2008.00006.x","article-title":"Probiotic pre-treatment reduces Gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats","volume":"1","author":"Al-Salami","year":"2008","journal-title":"Arch. Drug Inf."},{"issue":"4","key":"10.1016\/j.ejps.2017.05.041_bb0015","first-page":"532","article-title":"Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats","volume":"60","author":"Al-Salami","year":"2008","journal-title":"Pharmacol. Rep."},{"issue":"1","key":"10.1016\/j.ejps.2017.05.041_bb0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF03191383","article-title":"Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats","volume":"34","author":"Al-Salami","year":"2009","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.ejps.2017.05.041_bb0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s13318-011-0060-y","article-title":"Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats","volume":"37","author":"Al-Salami","year":"2012","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.ejps.2017.05.041_bb0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/10837450.2011.640685","article-title":"Evaluation of melt rheology of lactose-filled polyethylene glycol composites by means of capillary rheometery","volume":"18","author":"Bahramian","year":"2013","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejps.2017.05.041_bb0035","series-title":"The Merck Index","first-page":"146","article-title":"An encyclopedia of chemicals, drugs and biologicals","author":"Budavari","year":"1996"},{"key":"10.1016\/j.ejps.2017.05.041_bb0040","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1590\/S0102-86502003001100009","article-title":"Experimental model of induction of diabetes mellitus in rats","volume":"18","author":"Carvalho","year":"2003","journal-title":"Acta Cir. Bras."},{"issue":"3","key":"10.1016\/j.ejps.2017.05.041_bb0045","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.carbpol.2010.05.033","article-title":"NMR relaxometry and rheology of ionic and acid alginate gels","volume":"82","author":"de Celis","year":"2010","journal-title":"Carbohydr. Polym."},{"issue":"3","key":"10.1016\/j.ejps.2017.05.041_bb0050","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF02774276","article-title":"Physical-chemical properties of chenodeoxycholic acid and ursodeoxycholic acid","volume":"15","author":"Hisadome","year":"1980","journal-title":"Gastroenterol. Jpn."},{"issue":"1","key":"10.1016\/j.ejps.2017.05.041_bb0055","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2013.04.024","article-title":"Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy","volume":"170","author":"Khatun","year":"2013","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.ejps.2017.05.041_bb0060","first-page":"191","article-title":"Treatment of alloxan and streptozotocin diabetes in rats by intrafamiliar homo (allo) transplantation of neonatal pancreases","volume":"14","author":"Korec","year":"1980","journal-title":"Endocrinol. Exp."},{"key":"10.1016\/j.ejps.2017.05.041_bb0065","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/598603","article-title":"Deoxycholic acid as a modifier of the permeation of gliclazide through the blood brain barrier of a rat","volume":"2013","author":"Lali\u0107-Popovi\u0107","year":"2013","journal-title":"J.Diabetes Res."},{"issue":"12","key":"10.1016\/j.ejps.2017.05.041_bb0070","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1002\/ijc.24239","article-title":"Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor","volume":"124","author":"Lee","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.ejps.2017.05.041_bb0075","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.3109\/10717544.2015.1110846","article-title":"A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of type-1 diabetes","volume":"23","author":"Mathavan","year":"2016","journal-title":"Drug Deliv."},{"issue":"6","key":"10.1016\/j.ejps.2017.05.041_bb0080","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3109\/21691401.2015.1058807","article-title":"The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes","volume":"44","author":"Mathavan","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"1","key":"10.1016\/j.ejps.2017.05.041_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF03190984","article-title":"Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats","volume":"32","author":"Mikov","year":"2007","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.ejps.2017.05.041_bb0090","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF03191110","article-title":"The influence of 3\u03b1, 7\u03b1-dihydroxy-12-keto-5\u03b2-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes","volume":"33","author":"Mikov","year":"2008","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.ejps.2017.05.041_bb0095","doi-asserted-by":"crossref","first-page":"14451","DOI":"10.3390\/molecules200814451","article-title":"Absorption-enhancing effects of bile salts","volume":"20","author":"Moghimipour","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2017.05.041_bb0100","first-page":"1003","article-title":"Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study","volume":"8","author":"Mooranian","year":"2014","journal-title":"Drug. Des. Devel. Ther."},{"key":"10.1016\/j.ejps.2017.05.041_bb0105","first-page":"1221","article-title":"Microencapsulation as a novel delivery method for the potential antidiabetic drug, probucol","volume":"8","author":"Mooranian","year":"2014","journal-title":"Drug. Des. Devel. Ther."},{"key":"10.1016\/j.ejps.2017.05.041_bb0110","first-page":"1","article-title":"Advanced bile acid-based multi-compartmental microencapsulated pancreatic beta-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment","author":"Mooranian","year":"2014","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.ejps.2017.05.041_bb0115","first-page":"1673","article-title":"An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer","volume":"8","author":"Mooranian","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejps.2017.05.041_bb0120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12247-014-9182-5","article-title":"Stability and release kinetics of an advanced Gliclazide-Cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics","volume":"9","author":"Mooranian","year":"2014","journal-title":"J. Pharm. Innov."},{"issue":"1","key":"10.1016\/j.ejps.2017.05.041_bb0125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1208\/s12249-014-0205-9","article-title":"Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes","volume":"16","author":"Mooranian","year":"2015","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"10.1016\/j.ejps.2017.05.041_bb0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/02652048.2014.958204","article-title":"Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment","volume":"32","author":"Mooranian","year":"2015","journal-title":"J. Microencapsul."},{"issue":"6","key":"10.1016\/j.ejps.2017.05.041_bb0135","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3109\/10837450.2014.915570","article-title":"An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations","volume":"20","author":"Mooranian","year":"2015","journal-title":"Pharm. Dev. Technol."},{"issue":"5","key":"10.1016\/j.ejps.2017.05.041_bb0140","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s13346-015-0248-9","article-title":"The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study","volume":"5","author":"Mooranian","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejps.2017.05.041_bb0145","doi-asserted-by":"crossref","DOI":"10.1504\/IJNBM.2016.079684","article-title":"Viability and topographical analysis of microencapsulated \u03b2-cells exposed to a biotransformed tertiary bile acid: an ex vivo study","author":"Mooranian","year":"2016","journal-title":"Int. J. Nano Biomater."},{"issue":"7","key":"10.1016\/j.ejps.2017.05.041_bb0150","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3109\/21691401.2015.1069299","article-title":"Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: formulation characterization and effects on production of insulin and inflammation in a pancreatic beta-cell line","volume":"44","author":"Mooranian","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"5","key":"10.1016\/j.ejps.2017.05.041_bb0155","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3109\/21691401.2015.1024845","article-title":"Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes","volume":"44","author":"Negrulj","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.ejps.2017.05.041_bb0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cis.2013.11.016","article-title":"Microcapsule mechanics: from stability to function","volume":"207","author":"Neubauer","year":"2014","journal-title":"Adv. Colloid Interf. Sci."},{"issue":"5","key":"10.1016\/j.ejps.2017.05.041_bb0165","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/bdd.550","article-title":"Gliclazide: pharmacokinetic\u2013pharmacodynamic relationships in rats","volume":"28","author":"\u0160t\u011btinov\u00e1","year":"2007","journal-title":"Biopharm. Drug Dispos."},{"issue":"1","key":"10.1016\/j.ejps.2017.05.041_bb0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/10837450.2010.502898","article-title":"Bile salt-reinforced alginate-chitosan beads","volume":"17","author":"Takka","year":"2012","journal-title":"Pharm. Dev. Technol."},{"issue":"4","key":"10.1016\/j.ejps.2017.05.041_bb0175","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1023\/A:1015867305641","article-title":"Bile salt-fatty acid mixed micelles as nasal absorption promoters of peptides. II. In vivo nasal absorption of insulin in rats and effects of mixed micelles on the morphological integrity of the nasal mucosa","volume":"7","author":"Tengamnuay","year":"1990","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejps.2017.05.041_bb0180","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.intimp.2012.12.006","article-title":"Effects of taurocholic acid on immunoregulation in mice","volume":"15","author":"Wang","year":"2013","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2017.05.041_bb0185","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.intimp.2012.12.006","article-title":"Effects of taurocholic acid on immunoregulation in mice","volume":"15","author":"Wang","year":"2013","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.ejps.2017.05.041_bb0190","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/dom.12043","article-title":"Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans","volume":"15","author":"Wu","year":"2013","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.ejps.2017.05.041_bb0195","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/marc.200900901","article-title":"Fabrication of diverse microcapsule arrays of high density and good stability","volume":"31","author":"Yang","year":"2010","journal-title":"Macromol. Rapid Commun."},{"issue":"5","key":"10.1016\/j.ejps.2017.05.041_bb0200","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/mabi.201300474","article-title":"Improving stability and biocompatibility of alginate\/chitosan microcapsule by fabricating bi-functional membrane","volume":"14","author":"Zheng","year":"2014","journal-title":"Macromol. Biosci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717302695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717302695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T03:52:44Z","timestamp":1602129164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717302695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":40,"alternative-id":["S0928098717302695"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.05.041","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.05.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}